• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adapted vaccine strategy: facing the persistent challenges of COVID-19.

作者信息

Shang Lianhan, Cao Bin

机构信息

Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China; Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China.

出版信息

Lancet Infect Dis. 2023 Sep;23(9):984-985. doi: 10.1016/S1473-3099(23)00370-5. Epub 2023 Jun 19.

DOI:10.1016/S1473-3099(23)00370-5
PMID:37348518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10278996/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b07/10278996/c7dc8b524332/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b07/10278996/c7dc8b524332/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b07/10278996/c7dc8b524332/fx1_lrg.jpg

相似文献

1
Adapted vaccine strategy: facing the persistent challenges of COVID-19.适应性疫苗策略：应对新冠病毒的持续挑战
Lancet Infect Dis. 2023 Sep;23(9):984-985. doi: 10.1016/S1473-3099(23)00370-5. Epub 2023 Jun 19.
2
Challenges facing COVID-19 vaccination in India: Lessons from the initial vaccine rollout.印度新冠疫苗接种面临的挑战：首次疫苗推广的经验教训。
J Glob Health. 2021 Jun 26;11:03083. doi: 10.7189/jogh.11.03083.
3
COVID-19 vaccinations in The Gambia: efforts, challenges, and future directions.冈比亚的 COVID-19 疫苗接种：努力、挑战和未来方向。
Pan Afr Med J. 2022 Jun 30;42:164. doi: 10.11604/pamj.2022.42.164.34199. eCollection 2022.
4
Equal access of COVID-19 vaccine distribution in Africa: Challenges and way forward.非洲 COVID-19 疫苗分配的平等获取：挑战与前进道路。
J Med Virol. 2021 Sep;93(9):5212-5215. doi: 10.1002/jmv.27095. Epub 2021 May 28.
5
Foreword: Preventing COVID-19 Among the Immunocompromised Population.前言：预防免疫功能低下人群中的 COVID-19。
J Infect Dis. 2023 Aug 4;228(Suppl 1):S1-S3. doi: 10.1093/infdis/jiad106.
6
The politics of Covid-19 vaccine confidence.新冠疫苗信心的政治学。
Curr Opin Immunol. 2021 Aug;71:92-96. doi: 10.1016/j.coi.2021.06.007. Epub 2021 Jun 16.
7
COVID-19 vaccine challenges: What have we learned so far and what remains to be done?COVID-19 疫苗面临的挑战：到目前为止我们了解到了什么，还有什么需要做？
Health Policy. 2021 May;125(5):553-567. doi: 10.1016/j.healthpol.2021.03.013. Epub 2021 Mar 26.
8
COVID-19 Vaccines in Older Adults: Challenges in Vaccine Development and Policy Making.老年人的 COVID-19 疫苗：疫苗开发和政策制定中的挑战。
Clin Geriatr Med. 2022 Aug;38(3):605-620. doi: 10.1016/j.cger.2022.03.006. Epub 2022 Mar 21.
9
Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.恒河猴腺病毒 COVID-19 疫苗对小鼠适应 SARS-CoV-2 的保护效力。
J Virol. 2021 Nov 9;95(23):e0097421. doi: 10.1128/JVI.00974-21. Epub 2021 Sep 15.
10
Vaccine safety - is the SARS-CoV-2 vaccine any different?疫苗安全性 - SARS-CoV-2 疫苗有何不同？
Hum Vaccin Immunother. 2021 May 4;17(5):1322-1325. doi: 10.1080/21645515.2020.1829414. Epub 2020 Dec 3.

引用本文的文献

1
Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States.利用 SARS-CoV-2 测序数据鉴定美国全球新发传染病监测计划中的再感染病例。
Emerg Infect Dis. 2024;30(14):53-61. doi: 10.3201/eid3014.240231.
2
Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore.基于社区的调查对影响新加坡人接受和使用帕克洛维（奈玛特韦和利托那韦）作为 COVID-19 抗病毒药物的因素的见解。
BMC Public Health. 2024 Aug 28;24(1):2332. doi: 10.1186/s12889-024-19687-0.

本文引用的文献

1
Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.当前二价 COVID-19 疫苗中的祖先刺突导致深刻的免疫印迹。
Cell Rep Med. 2023 Nov 21;4(11):101258. doi: 10.1016/j.xcrm.2023.101258. Epub 2023 Oct 30.
2
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.奥密克戎 BA.1 含mRNA-1273 加强针与英国原始 COVID-19 疫苗的比较：一项随机、观察者盲、活性对照试验。
Lancet Infect Dis. 2023 Sep;23(9):1007-1019. doi: 10.1016/S1473-3099(23)00295-5. Epub 2023 Jun 19.
3
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster.
二价与单价加强针后的新型冠状病毒2中和抗体
Lancet Infect Dis. 2023 May;23(5):527-528. doi: 10.1016/S1473-3099(23)00181-0. Epub 2023 Mar 29.
4
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.早期估计，二价 mRNA 加强针在预防免疫功能正常成年人因奥密克戎 BA.5-和 XBB/XBB.1.5 相关亚谱系导致的有症状 SARS-CoV-2 感染方面的有效性-增加社区获得检测计划，美国，2022 年 12 月至 2023 年 1 月。
MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119-124. doi: 10.15585/mmwr.mm7205e1.
5
Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.二价奥密克戎 BA.1 适应型 BNT162b2 加强针在 55 岁以上成年人中的效果。
N Engl J Med. 2023 Jan 19;388(3):214-227. doi: 10.1056/NEJMoa2213082.
6
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.2022 年 9 月 8 日至 11 月 30 日，IVY 网络，18 个州，免疫功能正常的年龄≥65 岁成年人中，二价 mRNA 疫苗预防 COVID-19 相关住院的早期估计效力。
MMWR Morb Mortal Wkly Rep. 2022 Dec 30;71(5152):1625-1630. doi: 10.15585/mmwr.mm715152e2.
7
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution.印迹 SARS-CoV-2 体液免疫诱导奥密克戎 RBD 进化趋同。
Nature. 2023 Feb;614(7948):521-529. doi: 10.1038/s41586-022-05644-7. Epub 2022 Dec 19.
8
Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron.SARS-CoV-2 奥密克戎株感染性和免疫逃避的结构与功能特征。
Cell. 2022 Mar 3;185(5):860-871.e13. doi: 10.1016/j.cell.2022.01.019. Epub 2022 Jan 25.